Fig. 1
From: Transcriptional signatures of the BCL2 family for individualized acute myeloid leukaemia treatment
Flowchart of the study. From AML RNA-seq datasets (BeatAML, LeuceGene, and TCGA), gene optimization is independently conducted for capturing regulation factors of the BCL2 family. Afterward, the BCL2 family signatures (BFSigs) are calculated using the selected genes. Using the signatures, three novel subtypes are identified and functionally characterized. A classifier for predicting venetoclax response is developed and validated. Additionally, drug response analysis reveals the signature-based subtype-specific drug sensitivity. Finally, the validity of our selected genes is confirmed in a custom NanoString panel. *For external validation of BeatAML results, the BFSigs were re-extracted after batch effect correction